Navigation Links
Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

FRAZER, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the JP Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. Dr. Baldino will deliver a one hour presentation on Tuesday, January 8, 2008 beginning at 2:00 p.m. Pacific Time (11 a.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the investor relations section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous produc
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
5. DaVita Inc. to Present at JPMorgan Healthcare Conference
6. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
7. WebMD to Present at Upcoming Investor Conferences
8. Neurochem to present at JPMorgan Healthcare Conference
9. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
10. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
11. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...mmune response after antiretroviral therapy may be... 25 (HealthDay News) -- A new study challenges the... impairs the immune system,s ability to restore it...tive antiretroviral therapy (HAART). , From 50 ...re also infected with HCV. Intravenous drug use is...
(Date:7/25/2008)..., July 25 /PRNewswire/ -- BeaconEquity.com announc...ng news today., Investors can view all of the dai...conEquity.com/m , Today,s Trade Alerts include: D...rook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMe... ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis In...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...ios Spanos was shocked when his doctor discovered ... his body’s largest blood vessel, the aorta, durin...o symptoms, and was relieved to find out that the ...had been caught while it was still small. For the...
... A brewery in Japan launched production of unusual...farmer who was looking for ways to put his milk su...k will be available in the store shelves Thursday,...akashibetsu, on the country's northernmost island ...
... are planning to whiten your teeth by bleaching th...it done by unqualified people could cause consider...alons are offering teeth whitening by unqualified ...l bleach," said Christopher Orr, president of the ...
...tors and nurses who work in the developing world w...challenges, according to ‘Meeting the Health needs... The BMA’s International Committee surveyed 79 UK...including 67 doctors, who had recently worked in A...
Other Medicine News:Health News:Early Detection of Artery Weakening Can Be a Life-Saver 2Health News:Early Detection of Artery Weakening Can Be a Life-Saver 3Health News:Health Workers Need Better Preparation for Developing World 2
(Date:7/22/2008)...test awards under Therapeutics Development Initiat...tions to 23; next deadline January 20,2009, NEW ...f its mission to,speed delivery of transformative ... Michael J. Fox Foundation for Parkinson,s Researc... industry research teams. The awards,were granted ...
(Date:7/22/2008)... Regimens Including Lantus(R) and Apidra(R) Result...ith Type 2 Diabetes, Whatever the Algorithm ...., July 22 /- Results from the "Adjus...mple Algorithm to Carbohydrate,Counting for Adjust...blished in the American Diabetes Association,s (AD...
(Date:7/22/2008)...eveloped and Validated by Columbia University Medi...oprietary MicroRNA Technology, The Test Differen...ung Cancer (NSCLC), Classifying Squamous-Cell Car...ercent and Specificity of 90 Percent,This is the F... Sensitivity as Biomarkers for Accurate D...
(Date:7/22/2008)...lot Study Suggests That Ekkyo,s New Approach of LA...ly Improve Scar Healing Physiology, MARSEILLES, F...wn as,Heatwave Technology) a photomedicine company...s for skin scar prevention and reduction, announce... Lasers in Surgery and Medicine*,reporting the res...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Avantium and BP Extend Strategic Partnership 3782 1Avantium and BP Extend Strategic Partnership 3782 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 1ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 2ReBuilder Medical Technologies Inc Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical L 3779 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 1Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice 1286 2
... Useful in Cancer Treatment,Decisions , SALT LAKE ...ASDAQ: MYGN) (<a target="_blank" href=,"http://www...t,it presented studies for a new technology that m... a metastatic tumor, on Monday,April 16, 2007 at ... Cancer Research (AACR) in Los Angeles, California...
...r 19, 2007 - Antares Pharma, Inc.,(AMEX: AIS) anno...ite application study demonstrating that ANTUROL(R...sorbed on a bioequivalent,basis after a single-dos...ns., The study was an open-label, comparative thre...study. The trial enrolled 25,healthy subjects (80%...
Other Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
...y Biotech Captia™ Varicella- Zoster Virus (VZV...s intended for the detection and quantitative dete...dividual serum specimens may be used for the deter...convalescent, may be used to demonstrate seroconve...
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as
The Trinity Biotech Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the qualitative detection of IgM antibody in human serum to Mumps for the determination of immunological experi
The DIAGNOSTIC AUTOMATION, INC. (DAI) Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection and quantitative determination of IgG antibody to Mumps virus in human sera. In
Medicine Products: